Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
April 09, 2021 16:00 ET
|
Genmab A/S
Company Announcement FDA action date is Oct 10, 2021BLA submission supported by positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress...
Global Bi-Specific MAbS Market Report 2020: Market is Expected to Stabilize and Reach $6.12 Billion by 2023 - Long-term Forecast to 2025 & 2030
March 25, 2021 06:43 ET
|
Research and Markets
Dublin, March 25, 2021 (GLOBE NEWSWIRE) -- The "Bi-Specific MAbS Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Bi-Specific...
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
February 10, 2021 16:05 ET
|
Genmab A/S
Company Announcement Submission based on positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 COPENHAGEN, Denmark and BOTHELL,...
Global Antibody Partnering Terms and Agreements Directory 2020: Company A-Z, Headline Value, Stage of Development at Signing, Deal Component Type, Specific Therapy Target
February 05, 2021 06:53 ET
|
Research and Markets
Dublin, Feb. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Antibody Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering. The Global Antibody Partnering...
Growing at an annualized rate of over 12%, the ADC contract manufacturing market is estimated to reach close to USD 3 Billion by 2030, claims Roots Analysis
February 04, 2021 11:00 ET
|
Roots Analysis
London, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “ADC Contract Manufacturing Market (4th Edition), 2020-2030” report to its list of offerings. Manufacturing of...
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
January 04, 2021 14:00 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark, Jan. 04, 2021 Initiation of a global phase 3 trial for tisotumab vedotin versus investigator’s choice chemotherapy in recurrent or metastatic cervical cancer ...
Global Breast Cancer Monoclonal Antibodies Market Report 2020-2030: Focus on COVID-19 Growth and Changes
December 22, 2020 05:43 ET
|
Research and Markets
Dublin, Dec. 22, 2020 (GLOBE NEWSWIRE) -- The "Breast Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's...
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
September 21, 2020 10:20 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark and BOTHELL, Wash., 21 September 2020 Data featured in late-breaking proffered paper oral presentation Biologics license application submission planned to support...
Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020
August 26, 2020 18:05 ET
|
Genmab A/S
Media Release Copenhagen, Denmark, Aug 27, 2020 InnovaTV 204 study evaluated tisotumab vedotin in recurrent or metastatic cervical cancer Data from the study selected as a late-breaking abstract at...
GO Therapeutics appoints Dr. Robert J. Wills to Board of Directors
October 04, 2017 07:30 ET
|
GO Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2017 (GLOBE NEWSWIRE) -- GO Therapeutics, a company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer therapeutics against...